It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2010
  5. Otsuka Pharmaceutical Co., Ltd. and Fuso Pharmaceutical Industries, Ltd. Conclude Agreement for the Manufacturing and Commercialization of Therapeutic Cancer Vaccine, OTS102

January 26, 2010

Otsuka Pharmaceutical Co., Ltd.
Fuso Pharmaceutical Industries, Ltd.

Otsuka Pharmaceutical Co., Ltd. and Fuso Pharmaceutical Industries, Ltd. Conclude Agreement for the Manufacturing and Commercialization of Therapeutic Cancer Vaccine, OTS102

Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) (hereafter, Otsuka Pharmaceutical) and Fuso Pharmaceutical Industries, Ltd. (Head Office: Chuo-ku, Osaka, Japan; President: Mikio Toda) (hereafter, Fuso) today announced that they concluded an agreement on the manufacturing and commercialization in Japan of a therapeutic cancer vaccine OTS102, which is expected to inhibit angiogenesis.

Under the terms of agreement, Fuso, which was granted the exclusive rights to manufacture and commercialize OTS102 in Japan from OncoTherapy Science, Inc. (OTS), has sublicensed the manufacturing and commercialization rights to Otsuka Pharmaceutical. Otsuka Pharmaceutical shall pay Fuso an upfront payment as well as milestone payments and royalties. OTS will continue to develop OTS102, and Otsuka Pharmaceutical and Fuso will bear the development costs. After OTS102 is launched, Otsuka Pharmaceutical will manufacture the product, and both Otsuka Pharmacetuical and Fuso will commercialize the product under their own brand names.

Otsuka Pharmaceutical obtained the exclusive rights from OTS to develop, manufacture and commercialize several therapeutic peptide vaccines for pancreatic cancer, including OTS11101, in January 2008. With the agreement reached this time, Otsuka Pharmaceutical has obtained additional rights to manufacture and commercialize OTS102 in Japan. Otsuka Pharmaceutical will make continuous efforts on the research and development of cancer peptide vaccines, which are expected to become an innovative approach to cancer treatment, so as to provide new cancer treatment options on a worldwide basis.

Otsuka Pharmaceutical Co., Ltd. strives to contribute to the health of people around the world based on its corporate philosophy of 'Otsuka-people creating new products for better health worldwide.'

Corporate Information

OncoTherapy Science, Inc.

Established April 6, 2001
Representative Kensuke Tomita, President and CEO
Head office Kanagawa Science Park R&D D11F, 3-2-1 Sakado, Takatsu-ku, Kawasaki-shi, Kanagawa 213-0012, Japan
Business description Research on genes and gene products, diseases in which genes or gene products play a role, the development of associated therapeutic techniques, and the marketing of those techniques

Fuso Pharmaceutical Industries, Ltd.

Established March 25, 1937
Capital 10 billion 758 million yen
Representative Mikio Toda, President and Representative Director:
Head office 1-7-10 Doshomachi, Chuo-ku, Osaka 541-0045, Japan
No. of employees 1,358 (as of March 31, 2009)
Business description A manufacturer of ethical drugs, including dialysates for artificial kidneys (supplied to about 60% of 280,000 dialysis patients in Japan) and other agents related to blood and body fluids as the core products

Information in this news release was current as of the original release date.

Latest Corporate News Releases

Most Recent Releases